U.S. markets closed
  • S&P 500

    4,109.31
    +58.48 (+1.44%)
     
  • Dow 30

    33,274.15
    +415.12 (+1.26%)
     
  • Nasdaq

    12,221.91
    +208.43 (+1.74%)
     
  • Russell 2000

    1,802.48
    +34.10 (+1.93%)
     
  • Crude Oil

    75.70
    +1.33 (+1.79%)
     
  • Gold

    1,969.80
    -10.50 (-0.53%)
     
  • Silver

    24.24
    +0.25 (+1.03%)
     
  • EUR/USD

    1.0847
    -0.0062 (-0.56%)
     
  • 10-Yr Bond

    3.4940
    -0.0570 (-1.61%)
     
  • GBP/USD

    1.2332
    -0.0058 (-0.47%)
     
  • USD/JPY

    132.7970
    +0.1080 (+0.08%)
     
  • Bitcoin USD

    28,430.59
    +168.57 (+0.60%)
     
  • CMC Crypto 200

    621.79
    +7.58 (+1.23%)
     
  • FTSE 100

    7,631.74
    +11.31 (+0.15%)
     
  • Nikkei 225

    28,041.48
    +258.55 (+0.93%)
     

Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government’s pandemic response

Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government’s pandemic response

A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023. The company plans to boost spending on research and development to $4.5 billion this year, up from $3.3 billion in 2022. Separately, CureVac (CVAC) said preliminary data from its early stage trial for its COVID and seasonal flu shots had positive results to advance to the next stage of clinical testing.